Firebrick Pharma Limited
FRE.ASXHealth Care
Pharmaceutical development and manufacturing
Market Data
$0.042
+0.0%$12.0M
-100000.0x
$-0.011
0.00%
-0.3%
Latest Earnings
Appendix 4D & Half-Year Financial Report to 31 December 2025
24 February 2026
Firebrick Pharma reported a HY25 loss of $1.26M, improving 12.7% from the prior year, despite revenue falling 67.8% to $63K due to timing differences in distributor sales. The company successfully launched its new Nasodine Throat Spray product in Singapore and is expanding internationally, though auditors highlighted going concern uncertainties. Key points: Successfully launched new Nasodine Throat Spray in Singapore with manufacturing completed and shipments started; Net loss reduced by 12.7% to $1.26M despite revenue timing challenges; Strong user survey results showing 96% effectiveness rating and 97% ease of use
Recent Announcements
Appendix 4D & Half-Year Financial Report to 31 December 2025
Firebrick Pharma reported a HY25 loss of $1.26M, improving 12.7% from the prior year, despite revenue falling 67.8% to $63K due to timing differences in distributor sales. The company successfully launched its new Nasodine Throat Spray product in Singapore and is expanding internationally, though auditors highlighted going concern uncertainties. Key points: Successfully launched new Nasodine Throat Spray in Singapore with manufacturing completed and shipments started; Net loss reduced by 12.7% to $1.26M despite revenue timing challenges; Strong user survey results showing 96% effectiveness rating and 97% ease of use
Get real-time alerts for FRE
Receive AI-powered earnings summaries and instant notifications when Firebrick Pharma Limited releases results.
Register Free